CoChat

Non‐aspirin NSAIDs, cyclooxygenase‐2 inhibitors and risk for cardiovascular events–stroke, acute myocardial infarction, and death from coronary heart disease

Roumie, Christianne L., Choma, Neesha N., Kaltenbach, Lisa, Mitchel, Jr, Edward F., Arbogast, Patrick G., Griffin, Marie R. · 2009 · Pharmacoepidemiology and Drug Safety
Cited by 65

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Purpose: To determine if certain non‐steroidal anti‐inflammatory drugs (NSAIDs) are associated with increased risk of cardiovascular events: acute myocardial infarction (AMI), stroke, and death from coronary heart disease (CHD). Methods: We conducted a retrospective cohort study of Tennessee Medicaid enrollees aged 35–94 years between 1 January 1999 and 31 December 2005. Eligible persons were non‐institutionalized, had continuous enrollment, and had no serious illness prior to cohort entry. Exposure to celecoxib, rofecoxib, valdecoxib, ibuprofen, naproxen, diclofenac, and indomethacin was studied. The outcome was hospitalization for AMI, stroke, or death from CHD among those with and without a history of cardiovascular disease (CVD). Adjusted hazard ratios (aHR) and 95% confidence intervals (95% CI) are reported. Results: There were 610 001 persons in the final cohort and 14% had a baseline history of CVD. In those without CVD (N = 525 249) there were 1 566 678 person‐years of follow‐up and 12 184 events. In this group, non‐users had 7.90 events/1000 person‐years. Events/1000 person‐years were 10.41 for current use of celecoxib (aHR 1.00, 95% CI 0.89–1.13), 10.91 for rofecoxib (aHR 1.21, 95% CI 1.07–1.37), 12.46 for valdecoxib (aHR 1.30 95% CI 1.04–1.61), and 13.25 for indomethacin (aHR 1.36, 95% CI 1.11–1.66) compared to non‐users. Among patients with a past history of CVD (N = 84 752) there were 397 977 person‐years of follow‐up and 10 248 events. Non‐users had 28.30 events/1000 person‐years. Among those with CVD, rofecoxib use was associated with increased event rate (30.28 events/1000 person‐years [aHR 1.21, 95% CI 1.08–1.37]) and naproxen was associated with a decreased event rate (22.66 events/1000 person‐years [aHR 0.88, 95% CI 0.79–0.99]). Among new users, the results were similar except risk among naproxen users was no longer different than non‐users. Conclusions: We found an increased risk of cardiovascular events among all and new current users of rofecoxib, valdecoxib, and indomethacin in patients with no history of CVD. Among patients with CVD, all and new current rofecoxib use was associated with an increased risk of a cardiovascular event. Copyright © 2009 John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/pds.1820

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 65

Metadata

Authors
Roumie, C. L., Choma, N. N., Kaltenbach, L., Mitchel, Jr., Arbogast, P. G., & Griffin, M. R.
Venue
Pharmacoepidemiology and Drug Safety
Publisher
Wiley
Published
2009-07-27
Volume
18
Issue
11
Pages
1053-1063
ISSN
  • 1053-8569 (ISSN-L)
  • 1099-1557
OpenAlex
W2076263459
Cited by
65
References
5
FWCI
5.12
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Non‐aspirin NSAIDs, cyclooxygenase‐2 inhibitors and risk for cardiovascular events–stroke, acute myocardial infarction, and death from coronary heart disease. https://app.cochat.ai/papers/10.1002/pds.1820
The paper
Roumie, C. L., Choma, N. N., Kaltenbach, L., Mitchel, Jr., Arbogast, P. G., & Griffin, M. R. (2009). Non‐aspirin NSAIDs, cyclooxygenase‐2 inhibitors and risk for cardiovascular events–stroke, acute myocardial infarction, and death from coronary heart disease. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.1820

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.